Navigating a New Frontier in Hemophilia

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. 

This activity is supported by an educational grant from Novo Nordisk, Inc. 

Hemophilia care is entering a new era with innovative factor and nonfactor therapies designed to overcome persistent challenges such as inhibitor development, frequent dosing, and treatment burden. This activity will explore available and emerging next-generation agents, including mechanisms of action, pharmacokinetics, dosing strategies, and clinical implications in patient care. Current and emerging data from pivotal trials will be discussed, along with practical considerations for integrating these therapies into clinical practice. Through interactive, case-based scenarios, learners will gain insights into patient selection, switching protocols, and individualized treatment planning, ensuring a patient-centered approach to hemophilia management.

Target Audience: This initiative is intended for hematology and hematology/oncology HCPs and other clinicians who provide care to patients living with hemophilia.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph*rm*cy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Criteria for Success

Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].

Learning Objectives:

1. Distinguish the structure and biophysical function of approved and next-generation FVIIIa mimetics and the related impact on PK/PD and dosing

1. Evaluate clinical evidence on emerging FVIIIa mimetics as prophylaxis across varying hemophilia patient populations

1. Assess clinical considerations for integrating emerging FVIIIa mimetics into hemophilia management, including patient selection and switching from other therapies

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Catalyst Medical Education, LLC